Kristen McFadden
Nurse Practitioner · North Chelmsford, MANPI 1518405141
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 390 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,658, 4.1 times the $897 reported in 2022. Among nurse practitioner clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 390 payments — averaging $21.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Johnson & Johnson$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$748
- Gilead$573
- Pfizer$454
- plus $3K from 24 others
What the payments were for
- Food & beverage$8,452100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 85 | $1,362 |
| Johnson & Johnson | 57 | $1,225 |
| Takeda Pharmaceuticals U.S.A., Inc. | 46 | $1,037 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 52 | $748 |
| Gilead | 17 | $573 |
| Pfizer | 21 | $454 |
| Sanofi | 12 | $440 |
| Ardelyx, Inc. | 19 | $394 |
| Regeneron Healthcare Solutions, Inc. | 13 | $346 |
| Madrigal Pharmaceuticals | 7 | $249 |
| Lilly USA, LLC | 6 | $129 |
| Ironwood Pharmaceuticals, Inc | 5 | $126 |
| Janssen Scientific Affairs, LLC | 1 | $126 |
| Bristol Myers Squibb | 5 | $125 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Alnylam Pharmaceuticals Inc. | 5 | $123 |
| Ipsen Biopharmaceuticals, Inc | 4 | $109 |
| Phathom Pharmaceuticals, Inc. | 5 | $101 |
| Intercept Pharmaceuticals, Inc. | 5 | $98 |
| QOL Medical, LLC | 3 | $93 |
| Aimmune Therapeutics, Inc. | 4 | $89 |
| Boehringer Ingelheim | 3 | $85 |
| Ferring Pharmaceuticals Inc. | 4 | $73 |
| Daiichi Sankyo Inc. | 3 | $71 |
| Novo Nordisk | 2 | $41 |
| Nestle Healthcare Nutrition Inc. | 1 | $27 |
| Redhill Biopharma Inc. | 1 | $23 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Amgen | 1 | $21 |
| Braintree Laboratories, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,452 in reported general payments places this provider in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 102 | $75,279 |
| XifaxanRifaximin | 17 | $51,532 |
| MotegrityPrucalopride Succinate | 14 | $20,217 |
| TrulancePlecanatide | 19 | $11,398 |
| Colestipol Hcl | 55 | $5,570 |
| Omeprazole | 155 | $2,676 |
| Famotidine | 115 | $2,046 |
| Pantoprazole Sodium | 99 | $1,726 |
| Dicyclomine Hcl | 63 | $1,510 |
| Sucralfate | 13 | $1,233 |
| Esomeprazole Magnesium | 14 | $319 |
| Nortriptyline Hcl | 20 | $253 |
| Lactulose | 11 | $89 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $1,362 | $75,279102 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $748 | $62,93036 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $1,037 | $20,21714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,855 nurse practitioner providers in Massachusetts.
Other nurse practitioner in North Chelmsford
- Lauri WelchNorth Chelmsford$110K
- Teresa FogarenBoston$102K
- Carolyn MetivierBoston$93K
- Deborah GearySalem$80K
- Amberly ChaplinWorcester$56K
- Darlene MadoreBrockton$42K
- Nancy SydowN Chelmsford$35K
- Miu Lai NgBoston$33K
- Victoria Garcia AlbeaStoneham$31K
- Lauren BurkeBoston$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.